Your session is about to expire
← Back to Search
Mood Stabilizer
Lithium for COVID-19
Phase 2
Waitlist Available
Led By Thomas Guttuso, Jr., MD
Research Sponsored by State University of New York at Buffalo
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 21
Awards & highlights
Summary
This trial will test if a small dose of lithium can help people who have ongoing symptoms after recovering from COVID-19. Initially, participants will receive different treatments for a few weeks. After that, all participants will receive lithium for a short period. The goal is to see if lithium can improve their symptoms by balancing brain chemicals.
Eligible Conditions
- COVID-19
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 21
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 21
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Brain Fog Severity Scale
Fatigue Severity Scale
Secondary study objectives
Delayed Recall Test
Desire to Continue Therapy
Trigger Finger Disorder
+7 moreSide effects data
From 2012 Phase 4 trial • 46 Patients • NCT0059662233%
headaches
11%
Increased appetite
11%
Drymouth
11%
dizziness
11%
heart palpitations
7%
blurred vision
7%
forgetfulness
7%
bad taste
100%
80%
60%
40%
20%
0%
Study treatment Arm
Bipolar Participants Treated
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: LithiumExperimental Treatment1 Intervention
Lithium 10mg po qd
Group II: PlaceboPlacebo Group1 Intervention
Placebo identically matching the lithium pills
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lithium
2001
Completed Phase 4
~2470
Find a Location
Who is running the clinical trial?
State University of New York at BuffaloLead Sponsor
264 Previous Clinical Trials
52,050 Total Patients Enrolled
3 Trials studying COVID-19
61 Patients Enrolled for COVID-19
University at BuffaloLead Sponsor
132 Previous Clinical Trials
98,883 Total Patients Enrolled
National Center for Advancing Translational Sciences (NCATS)NIH
342 Previous Clinical Trials
410,418 Total Patients Enrolled
21 Trials studying COVID-19
267,497 Patients Enrolled for COVID-19
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- Your score on the Beck Depression Inventory II is less than 24.You have been experiencing tiredness and difficulty concentrating or remembering things for at least four weeks after having COVID-19.You feel very tired or have trouble thinking clearly, with scores of 28 or higher on the Fatigue Severity Scale or the Brain Fog Severity Scale.You have never had fibromyalgia, chronic fatigue syndrome, or any progressive cognitive disorder before getting infected with COVID-19.You haven't used tobacco or marijuana products for more than 6 months, and you are not currently abusing alcohol (drinking 4 or more drinks per day) or using illegal drugs.
Research Study Groups:
This trial has the following groups:- Group 1: Lithium
- Group 2: Placebo
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger